Lifecore Biomedical
This article was originally published in The Gray Sheet
Executive Summary
Supplier of hyaluronic acid biomaterials for medical applications is acquired by diversified materials science firm Landec Corporation for $40 million up-front, plus assumed debt of $4 million and up to $10 million in future milestone payments. Lifecore Biomedical went private in a 2008 buyout deal with private equity firm Warburg Pincus; Lifecore's dental unit then merged with Warburg Pincus portfolio firm Keystone Dental (1"The Gray Sheet" Feb. 18, 2008)
You may also be interested in...
Lifecore Set To Go Private Under $239 Million Warburg Pincus Buyout Deal
Dental implant maker Lifecore Biomedical is on-track to be acquired by private equity firm Warburg Pincus for $239 million after failing to receive a superior proposal, the firm said Feb. 14
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.